FEB 10, 2016 12:55 PM PST

Overexpression of Certain Genes Makes a Certain Pancreatic Cancer More Lethal

WRITTEN BY: Kara Marker
Scientists from the University of North Carolina at Charlotte, North Carolina Central University’s Nutrition Research Program at the NC Research Campus in Kannapolis, NC, and the Carolinas Medical Center in Charlotte, NC have teamed up to identify molecular targets in the signaling pathway for pancreatic ductal adenocarcinoma tumors. Their study was published in the journal Oncogene last month.
 
Pancreatic ductal adenocarcinoma (PDA) is a highly lethal type of cancer, with only three to five percent of people surviving five years after diagnosis (Genes & Development). PDA constitutes about 90 percent of all pancreatic cancers, which was responsible for over 40,000 deaths in the United States in 2015 (National Cancer Institute). By investigating the key molecular players in the signaling pathway that leads to tumor growth, these researchers may have found a way to block this communication to reduce cancer growth.
 


Mucin1 (MUC1) is a transmembrane glycoprotein that, in addition to intracellular signaling, is involved in developing protective mucous barriers on epithelial surfaces (Gene ID). MUC1 is overexpressed in more than 80 percent of PDA cases, which lead the team of researchers from North Carolina to look further at the role of MUC1 in tumor growth.
 
MUC1 creates a pro-angiogenic tumor microenvironment, forming a network of blood vessels for the abnormally growing tissues to access. MUC1 does so by activating neuropilin-1 (NRP1), also a transmembrane protein and a co-receptor of vascular endothelial growth factor (VEGF) and its ligand.
 
PDA cells with high levels of tumor-associated MUC1 (tMUC1) and subsequently high levels of NRP1 induce cancer-friendly conditions through signaling with VEGF with a few different actions observed in this study.
  1. They induce endothelial cell tube formation.
  2. They generate abnormally positioned blood vessels.
  3. They enhance distant metastasis (as observed in a zebrafish xenograft model).
PDA cells with tMUC1 also induce N-cadherin and Vimentin, two proteins needed for the epithelial to mesenchymal transition.
 
The relationship between MUC1, NRP1, and VEGF produces an “attractive therapeutic target” for suppressing PDA tumors, and the researchers from this study uniquely demonstrated that tMUC1 does indeed prompt high levels of NRP1 that lead to a pro-angiogenic tumor microenvironment that does not exist in PDA tumors with low to zero levels of tMUC1. Inhibiting signaling between NRP1 and VEGF suppresses tumor growth, as the team saw in mice models of disease. They did so with an NRP1 antagonist that inhibits the communication between VEGF and NRP1, to cut off all pro-tumor reactions that lead to more lethal cancer growth.
 
Next, the scientists plan to confirm that inhibiting NRP1 and VEGF signaling in humans produces the same effect of tumor suppression. From there, new therapeutics for PDA can be developed. 
 

Source: Oncogene
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
DEC 09, 2019
Cell & Molecular Biology
DEC 09, 2019
Insight Into the Epigenetic Mechanisms Controlling Cellular Identity
Every cell type has to carefully control which genes are expressed, and new research has learned more about that process....
DEC 09, 2019
Genetics & Genomics
DEC 09, 2019
Can Autism be Diagnosed from Blood Tests?
Diagnosing Autism Spectrum Disorder (ASD) early on in life through behavioral signs alone has been difficult. This comes as typical markers for the conditi...
DEC 09, 2019
Genetics & Genomics
DEC 09, 2019
A More Precise Version of CRISPR/Cas9 is Created
A more accurate version of Cas9 has been created, reducing the number of off-target effects. It may be better suited for use in gene therapy....
DEC 09, 2019
Neuroscience
DEC 09, 2019
Autism May be Linked to an Immune Disorder
Until now, diagnosis for autism spectrum disorder have relied on behavioral assessments looking for symptoms including poor social and communication skills...
DEC 09, 2019
Genetics & Genomics
DEC 09, 2019
Super-Resolution Microscopy Reveals How DNA Damage is Repaired
People that don't carry functional copies of these proteins are more likely to get diseases that arise from unstable DNA....
DEC 09, 2019
Genetics & Genomics
DEC 09, 2019
Evaluating the Genetic Damage Caused by Cancer Treatments
Now that we know more about the impact of some cancer treatments, they can be applied optimally....
Loading Comments...